Citations

Clear

4207 citation(s) found for "Chen, Yu".

Testing for HER2 in Breast Cancer: A Continuing Evolution
Shah, Sejal , Chen, Beiyun

Mayo Clinic

Pathology Research International | December 6, 2010 | Volume: 2011 | Issue: No issue available | Pages: 1-16

10.4061/2011/903202 | PMID 21188214 Get It

Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor in breast cancer. HER2 is overexpressed in approximately 15%–20% of invasive breast carcinomas and is associated with earlier recurrence, shortened disease free survival, and poor prognosis. Trastuzumab (Herceptin) a “humanized” monoclonal antibody targets the extracellular domain of HER2 and is widely used in the management of HER2 positive breast cancers. Accurate assessment of HER2 is thus critical in the management of breast cancer. The aim of this paper is to present a comprehensive review of HER2 with reference to its discovery and biology, clinical significance, prognostic value, targeted therapy, current and new testing modalities, and the interpretation guidelines and pitfalls.
Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults
Omenetti, Alessia , Yang, Liu , Gainetdinov, Raul R. , Guy, Cynthia D. , Choi, Steve S. , Chen, Wei , Caron, Marc G. , Diehl, Anna Mae , Yang, Liu

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | November 11, 2010 | Volume: 300 | Issue: 2 | Pages: G303-G315

10.1152/ajpgi.00368.2010 | PMID 21071507 Get It

Paracrine signaling between cholangiocytes and stromal cells regulates biliary remodeling. Cholangiocytes have neuroepithelial characteristics and serotonin receptor agonists inhibit their growth, but whether they are capable of serotonin biosynthesis is unknown. We hypothesized that cholangiocytes synthesize serotonin and that cross talk between liver myofibroblasts (MF) and cholangiocytes regulates this process to influence biliary remodeling. Transwell cultures of cholangiocytes ± MF, and tryptophan hydroxylase-2 knockin (TPH2KI) mice with an inactivating mutation of the neuronal tryptophan hydroxylase (TPH) isoform, TPH2, were evaluated. Results in the cell culture models confirm that cholangiocytes have serotonin receptors and demonstrate for the first time that these cells express TPH2 and produce serotonin, which autoinhibits their growth but stimulates MF production of TGF-β1. Increased TGF-β1, in turn, counteracts autocrine inhibition of cholangiocyte growth by repressing cholangiocyte TPH2 expression. Studies of TPH2KI mice confirm that TPH2-mediated production of serotonin plays an important role in remodeling damaged bile ducts because mice with decreased TPH2 function have reduced biliary serotonin levels and exhibit excessive cholangiocyte proliferation, accumulation of aberrant ductules and liver progenitors, and increased liver fibrosis after bile duct ligation. This new evidence that cholangiocytes express the so-called neuronal isoform of TPH, synthesize serotonin de novo, and deploy serotonin as an autocrine/paracrine signal to regulate regeneration of the biliary tree complements earlier work that revealed that passive release of serotonin from platelets stimulates hepatocyte proliferation. Given the prevalent use of serotonin-modulating drugs, these findings have potentially important implications for recovery from various types of liver damage.
Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease
Blazer‐Yost, Bonnie L. , Haydon, Julie, Eggleston‐Gulyas, Tracy, Chen, Jey‐Hsin, Gattone, Vincent H., Wang, Xiaofang , Torres, Vicente E.

Mayo Clinic

PPAR Research | November 1, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-8

10.1155/2010/274376 | PMID 21052534 Get It

Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPAR γ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl − transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl − secretory response to vasopressin in cultured renal cells, it is hypothesized that PPAR γ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPAR γ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.
A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension
Cataliotti, Alessandro , Boerrigter, Guido, Chen, Horng H. , Sangaralingham, S. Jeson , Martín, Fernando L., Ichiki, Tomoko , Burnett, John C. , McKie, Paul M. , Sangaralingham, S. Jeson

Mayo Clinic

Hypertension | October 26, 2010 | Volume: 56 | Issue: 6 | Pages: 1152-1159

10.1161/hypertensionaha.110.159210 | PMID 20975033 Get It

M-atrial natriuretic peptide (ANP; M-ANP) is a novel next generation 40 amino acid peptide based on ANP, which is highly resistant to enzymatic degradation and has greater and more sustained beneficial actions compared with ANP. The current study was designed to advance our understanding of the therapeutic potential of M-ANP in a canine model of acute angiotensin II–induced hypertension with elevated cardiac filling pressures and aldosterone activation. We compare M-ANP with vehicle and equimolar human B-type natriuretic peptide, which possesses the most potent in vivo actions of the native natriuretic peptides. M-ANP significantly lowered mean arterial pressure and systemic vascular resistance. Importantly, despite a reduction in blood pressure, renal function was enhanced with significant increases in renal blood flow, glomerular filtration rate, diuresis, and natriuresis after M-ANP infusion. Although angiotensin II induced an acute increase in pulmonary capillary wedge pressure, M-ANP significantly lowered pulmonary capillary wedge pressure, pulmonary artery pressure, and right atrial pressure. Further, M-ANP significantly suppressed angiotensin II–induced activation of aldosterone. These cardiovascular and renal enhancing actions of M-ANP were accompanied by significant increases in plasma and urinary cGMP, the second messenger molecule of the natriuretic peptide system. When compared with human B-type natriuretic peptide, M-ANP had comparable cardiovascular actions but resulted in a greater natriuretic effect. These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension.
Generalized response of a sphere embedded in a viscoelastic medium excited by ultrasound radiation force.
Urban, Matthew W. , Nenadic, Ivan , Greenleaf, James F. , Chen, Shigao , Urban, Matthew W

Mayo Clinic

The Journal of the Acoustical Society of America | October 19, 2010 | Volume: 128 | Issue: 4_Supplement | Pages: 2337-2337

10.1121/1.3508269 Get It

Characterization of viscoelastic soft tissues and materials has been a subject of active research for the past two decades. Techniques involving measuring the motion of embedded spheres in viscoelastic media have been employed to measure the viscoelastic material properties of the media surrounding the sphere. The published work using this technique has been restricted to using the Kelvin–Voigt model, which has worked for gelatin-based materials. We report an extension of this method using different viscoelastic rheological models such as the Maxwell, generalized Maxwell, Zener, and Kelvin–Voigt fractional derivative models. We performed experiments using a focused 3-MHz transducer to produce radiation force and a 7.5-MHz pulse-echo transducer to measure the sphere motion. Two phantoms were tested; one made of gelatin and another made of rubber with stainless steel spheres embedded in the materials. The response was fitted with the generalized theoretical model to find the material properties over bandwidths of 25–3000 Hz. The median absolute errors ranged from 0.0036–0.0421 and 0.0365–0.0879 for the gelatin and rubber phantoms, respectively. This generalized method offers added flexibility to characterize different types of viscoelastic materials using the most appropriate rheological model. [Work supported in part by NIH Grant nos. EB002167 and DK082408.]
Cdc20 hypomorphic mice fail to counteract de novo synthesis of cyclin B1 in mitosis
Malureanu, Liviu, Jeganathan, Karthik B. , Baker, Darren J. , Ree, Janine H. van, Gullon, Oliver, Chen, Zheyan , Henley, John R. , Deursen, Jan M. van , Jin, Fang , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

Journal of Cell Biology | October 18, 2010 | Volume: 191 | Issue: 2 | Pages: 313-329

10.1083/jcb.201003090 | PMID 20956380 Get It

Cdc20 is an activator of the anaphase-promoting complex/cyclosome that initiates anaphase onset by ordering the destruction of cyclin B1 and securin in metaphase. To study the physiological significance of Cdc20 in higher eukaryotes, we generated hypomorphic mice that express small amounts of this essential cell cycle regulator. In this study, we show that these mice are healthy and not prone to cancer despite substantial aneuploidy. Cdc20 hypomorphism causes chromatin bridging and chromosome misalignment, revealing a requirement for Cdc20 in efficient sister chromosome separation and chromosome–microtubule attachment. We find that cyclin B1 is newly synthesized during mitosis via cytoplasmic polyadenylation element–binding protein-dependent translation, causing its rapid accumulation between prometaphase and metaphase of Cdc20 hypomorphic cells. Anaphase onset is significantly delayed in Cdc20 hypomorphic cells but not when translation is inhibited during mitosis. These data reveal that Cdc20 is particularly rate limiting for cyclin B1 destruction because of regulated de novo synthesis of this cyclin after prometaphase onset.
O3‐06‐08: Sample size estimates for pre‐symptomatic Alzheimer's disease treatment/surrogate marker development trials in Apolipoprotein E4 homozygotes close to their estimated age at symptomatic onset
Reiman, Eric M. , Fleisher, Adam , Ayutyanont, Napatkamon , Reschke, Cole, Bandy, Dan, Reeder, Stephanie, Henslin, Bruce R. , Yee-Benedetto, Sandra C.H., Tariot, Piere N., Keppler, Jennifer, Alexander, Gene E. , Caselli, Richard J. , Chen, Kewei , Dueck, Amylou C. , Langbaum, Jessica B. S. , Liu, Xiaofen , Reeder, Stephanie, Pn, Tariot

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2010.05.434 Get It

P1‐072: Using APOE to predict “imminent” risk of Alzheimer's disease conversion among patients with MCI: The REVEAL Study
Lautenbach, Denise, Chen, Clara A. , Roberts, J. Scott , Petersen, Ronald , Cupples, L. Adrienne , Green, Robert C.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2010.05.620 Get It

Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction
Boilson, Barry A. , Larsen, Katarína, Harbuzariu, Adriana , Delacroix, Sinny , Kořínek, Josef , Froehlich, Harald , Bailey, Kent R. , Scott, Christopher G. , Shapiro, Brian P. , Boerrigter, Guido, Chen, Horng H. , Redfield, Margaret M. , Burnett, John C. , Simari, Robert D., Scott, Christopher

Mayo Clinic

Circulation: Heart Failure | June 24, 2010 | Volume: 3 | Issue: 5 | Pages: 635-642

10.1161/circheartfailure.109.879437 | PMID 20573992 Get It

Background— Reductions in numbers of circulating progenitor cells (CD34+ cell subsets) have been demonstrated in patients at risk for, or in the presence of, cardiovascular disease. The mediators of these reductions remain undefined. To determine whether neurohumoral factors might regulate circulating CD34+ cell subsets in vivo, we studied complementary canine models of left ventricular (LV) dysfunction. Methods and Results— A pacing model of severe LV dysfunction and a hypertensive renal wrap model in which dogs were randomized to receive deoxycorticosterone acetate (DOCA) were studied. Circulating CD34+ cell subsets including hematopoietic precursor cells (HPCs: CD34+/CD45 dim /VEGFR2−) and endothelial progenitor cells (EPCs: CD34+/CD45−/VEGFR2+) were quantified. Additionally, the effect of mineralocorticoid excess on circulating progenitor cells in normal dogs was studied. The majority of circulating CD34+ cells expressed CD45dimly and did not express VEGFR2, consistent with an HPC phenotype. HPCs were decreased in response to pacing, and this decrease correlated with plasma aldosterone levels (Spearman rank correlation=−0.67, P =0.03). In the hypertensive renal wrap model, administration of DOCA resulted in decreased HPCs. No changes were seen in EPCs in either model. Normal dogs treated with DOCA exhibited a decrease in HPCs in peripheral blood but not bone marrow associated with decreased telomerase activity. Conclusions— This is the first study to demonstrate that mineralocorticoid excess, either endogenous or exogenous, results in reduction in HPCs. These data suggest that mineralocorticoids may induce accelerated senescence of progenitor cells, leading to their reduced survival and decline in numbers.